Ankiand Pharma India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth 80.28%
- Ebitda 80.28%
- Net Worth -18.46%
- Total Assets 374.34%
About Ankiand Pharma India
Ankiand Pharma India Private Limited (APIPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 19 September 2019 (Five years and five months 3 days old ). Its registered office is in Varanasi, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Prem Pandey and Gayatri Pandey serve as directors at the Company.
Company Details
- Location
Varanasi, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24299UP2019PTC121425
- Company No.
121425
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Sep 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Ankiand Pharma India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prem Pandey  | Director | 19-Sep-2019 | Current |
| Gayatri Pandey | Director | 19-Sep-2019 | Current |
Financial Performance of Ankiand Pharma India.
Ankiand Pharma India Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 80.28% increase in profit. The company's net worth observed a substantial decline by a decrease of 18.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ankiand Pharma India?
In 2023, Ankiand Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shristimed India Private LimitedPrem Pandey and Gayatri Pandey are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ankiand Pharma India?
Unlock and access historical data on people associated with Ankiand Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ankiand Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ankiand Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.